Florian Hornsteiner, Janine Vierthaler, Helen Strandt, Antonia Resag, Zhe Fu, Markus Ausserhofer, Christoph H Tripp, Sophie Dieckmann, Markus Kanduth, Kathryn Farrand, Sarah Bregar, Niloofar Nemati, Natascha Hermann-Kleiter, Athanasios Seretis, Sudhir Morla, David Mullins, Francesca Finotello, Zlatko Trajanoski, Guido Wollmann, Franca Ronchese, Marc Schmitz, Ian F Hermans, Patrizia Stoitzner
BACKGROUND: Tumor-targeted therapy causes impressive tumor regression, but the emergence of resistance limits long-term survival benefits in patients. Little information is available on the role of the myeloid cell network, especially dendritic cells (DC) during tumor-targeted therapy. METHODS: Here, we investigated therapy-mediated immunological alterations in the tumor microenvironment (TME) and tumor-draining lymph nodes (LN) in the D4M.3A preclinical melanoma mouse model (harboring the V-Raf murine sarcoma viral oncogene homolog B (BRAF)V600E mutation) by using high-dimensional multicolor flow cytometry in combination with multiplex immunohistochemistry...
April 17, 2024: Journal for Immunotherapy of Cancer